Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2020-10-02
Target enrollment:
Participant gender:
Summary
This randomized (2:1), multi-center, placebo-controlled, phase II efficacy study is designed
to compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI
(ARM B) in patients with mCRC previously treated with a FOLFOX regimen.